Juncture Wealth Strategies LLC Purchases Shares of 5,538 Corcept Therapeutics Incorporated (NASDAQ:CORT)

Juncture Wealth Strategies LLC acquired a new position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 5,538 shares of the biotechnology company's stock, valued at approximately $633,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. KBC Group NV increased its position in Corcept Therapeutics by 45.9% during the fourth quarter. KBC Group NV now owns 4,118 shares of the biotechnology company's stock worth $208,000 after acquiring an additional 1,296 shares during the period. Pacer Advisors Inc. increased its holdings in shares of Corcept Therapeutics by 18.3% during the fourth quarter. Pacer Advisors Inc. now owns 10,896 shares of the biotechnology company's stock worth $549,000 after purchasing an additional 1,689 shares during the period. Meritage Portfolio Management raised its position in shares of Corcept Therapeutics by 10.3% in the fourth quarter. Meritage Portfolio Management now owns 29,811 shares of the biotechnology company's stock valued at $1,502,000 after buying an additional 2,783 shares in the last quarter. Empowered Funds LLC raised its position in shares of Corcept Therapeutics by 6.5% in the fourth quarter. Empowered Funds LLC now owns 41,048 shares of the biotechnology company's stock valued at $2,068,000 after buying an additional 2,507 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. bought a new stake in shares of Corcept Therapeutics in the fourth quarter valued at approximately $58,000. Institutional investors and hedge funds own 93.61% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Wall Street Zen lowered Corcept Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, May 14th. Piper Sandler raised their price target on Corcept Therapeutics from $128.00 to $131.00 and gave the stock an "overweight" rating in a research report on Thursday, April 3rd. Canaccord Genuity Group increased their price objective on shares of Corcept Therapeutics from $130.00 to $142.00 and gave the stock a "buy" rating in a research note on Tuesday, April 1st. Truist Financial set a $135.00 target price on shares of Corcept Therapeutics in a research report on Tuesday, May 6th. Finally, HC Wainwright cut their price target on shares of Corcept Therapeutics from $150.00 to $145.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $138.25.

Corcept Therapeutics Price Performance

NASDAQ:CORT traded up $0.47 during trading hours on Wednesday, hitting $69.98. The company's stock had a trading volume of 1,141,760 shares, compared to its average volume of 1,147,539. Corcept Therapeutics Incorporated has a twelve month low of $28.04 and a twelve month high of $117.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The stock has a fifty day simple moving average of $73.08 and a 200-day simple moving average of $63.57. The company has a market capitalization of $7.42 billion, a P/E ratio of 55.54 and a beta of 0.22.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last posted its earnings results on Monday, May 5th. The biotechnology company reported $0.17 EPS for the quarter, hitting analysts' consensus estimates of $0.17. The firm had revenue of $157.21 million during the quarter, compared to analysts' expectations of $177.93 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The business's revenue for the quarter was up 7.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.25 earnings per share. On average, analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 EPS for the current fiscal year.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, insider Sean Maduck sold 100,000 shares of the company's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $100.54, for a total value of $10,054,000.00. Following the completion of the transaction, the insider now directly owns 85,622 shares in the company, valued at approximately $8,608,435.88. This represents a 53.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Joseph Douglas Lyon sold 421 shares of Corcept Therapeutics stock in a transaction on Monday, March 24th. The stock was sold at an average price of $60.58, for a total transaction of $25,504.18. Following the transaction, the insider now owns 9,009 shares in the company, valued at approximately $545,765.22. This trade represents a 4.46% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 275,125 shares of company stock worth $23,619,296 over the last quarter. Corporate insiders own 20.80% of the company's stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.